Shares of Vertex Pharmaceuticals rose after Journavx, the company’s oral non-opioid pain medication, received Food and Drug Administration approval.
The Boston drugmaker (Nasdaq: VRTX) says it put more than two decades of work into developing and bringing the new medicine to market. Stuart Arbuckle, Vertex’s chief operating officer ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results